Rituximab vs placebo
Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
- OR 1.14 [0.75, 1.73]1 study · 439 participantsLow